ongoing trial of abemaciclib and pembrolizumab in hr /her2-negative breast cancer
Published 7 years ago • 446 plays • Length 1:33Download video MP4
Download video MP3
Similar videos
-
2:42
phase ii results for abemaciclib in pretreated hr /her2-negative breast cancer
-
0:52
exploring abemaciclib for the treatment of brain metastases in hr /her2- breast cancer
-
1:13
significance of the monarch 2 findings for abemaciclib in hr /her2- breast cancer
-
1:55
dr. tolaney on abemaciclib plus pembrolizumab for hr , her2- breast cancer
-
2:23
an overview of the neomonarch trial in hr /her2- breast cancer
-
1:19
advantages to treating hr patients with breast cancer with abemaciclib
-
5:06
safety outcomes in the phase iii monarche trial of abemaciclib et in hr , her2- breast cancer
-
1:39
abemaciclib for hr /her2- advanced or metastatic breast cancer
-
2:22
cdk4/6 inhibitors in early stage hr /her2- disease
-
2:28
expert discusses promise of abemaciclib for breast cancer treatment
-
5:32
esmo 2020 expert video report on cdk4 6i in the adjuvant treatment of breast cancer
-
3:06
age-stratified findings from the monarche trial of abemaciclib in breast cancer
-
1:41
dr. tolaney on activity with abemaciclib in patients with hr /her2– breast cancer
-
4:45
abemaciclib monotherapy’s role in hr breast cancer
-
1:07
phase ii results for pembrolizumab monotherapy in metastatic tnbc
-
3:58
promise breast cancer clinical trial
-
1:40
continuous abemaciclib treatment leads to breast cancer inhibition | oncotarget
-
3:22
managing recurrent metastatic er /her2- breast cancer
-
6:39
expert report on advances in the management of her2-negative and her2-low advanced breast cancer